AmgenAMGN

關於Amgen

Amgen is one of the world's largest independent biotechnology companies, developing and manufacturing human therapeutics derived from advances in cellular and molecular biology. Its portfolio centers on biologic medicines for serious illnesses, spanning inflammation, oncology, bone health, cardiovascular disease, nephrology, and rare disease. Long-established franchises include Enbrel in rheumatology, Prolia and Xgeva in bone-related conditions, Otezla in psoriasis and psoriatic arthritis, Repatha in cardiovascular disease, and a growing oncology stable including Blincyto, Kyprolis, and the KRAS inhibitor Lumakras. A cluster of large, high-margin biologics generates the bulk of profit, while a biosimilars unit and legacy supportive-care products such as Neulasta contribute a smaller and more competitively pressured share of sales.

Serious holders track the durability of Amgen's mature biologics against biosimilar erosion, particularly for products whose exclusivity has already lapsed or is nearing expiry, and the pace at which newer launches offset those declines. Pipeline execution in obesity, oncology, and inflammation is watched closely, alongside regulatory outcomes at the FDA and EMA and pricing dynamics under the U.S. Inflation Reduction Act's Medicare negotiation regime. Concentration in a handful of large drugs, exposure to pharmacy benefit manager rebate structures, integration progress on the Horizon Therapeutics acquisition and the associated debt load, capital return policy through dividends and buybacks, and manufacturing footprint including Puerto Rico all figure in the standing questions.

Amgen was founded in 1980 in Thousand Oaks, California, and reached commercial scale in the late 1980s with Epogen for anemia in dialysis patients, followed by Neupogen for chemotherapy-induced neutropenia; those launches established recombinant protein therapeutics as a viable industry. Subsequent decades brought internal development of Enbrel, Aranesp, Prolia, and Repatha, along with expansion via acquisitions including Immunex in 2002, Onyx Pharmaceuticals in 2013, and the Otezla asset from Celgene in 2019. The 2023 completion of the Horizon Therapeutics transaction added rare-disease franchises led by Tepezza, Krystexxa, and Uplizna, and reshaped the therapeutic mix toward specialty and rare indications.

Revenue is generated primarily through prescription sales to wholesalers, specialty distributors, hospitals, clinics, and integrated health systems, with end demand shaped by physician prescribing and payer coverage. In the United States, the largest market, net pricing is heavily influenced by rebate negotiations with pharmacy benefit managers, Medicare and Medicaid rules, and 340B discount obligations; international sales flow through national health systems and tender processes, with a meaningful minority of revenue coming from outside the United States. Competitive position rests on manufacturing scale in biologics, patent estates, clinical-trial breadth, and biosimilar defense, positioning Amgen against large-cap peers including Johnson & Johnson, Merck, Pfizer, Bristol-Myers Squibb, AbbVie, Regeneron, and Novartis.

公司簡介由LineVest編輯部撰寫。屬新聞報導，非投資建議。 委託撰寫Amgen的SEC完整報告 →